Spruce Biosciences, Inc. SPRB
46.38 USD -0.28 (-0.61%)
Nov 11, 2026, 10:49 AM EST
46.19 Day range 47.14
38.06 52-week range 127.90
- YTD
- -46.76%
- 1 year
- -58.83%
News
benzinga.com Spruce Biosciences Q3 EPS $(8.51) Up From $(14.58) YoY Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(8.51) per share. This is a 41.63 percent increase over losses of $(14.58) per share from the same period last year.
businesswire.com Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
benzinga.com Spruce Biosciences Separates CRHX-101 Program Into Adrenyx Biosciences, Plans Spin-Off To Stockholders Transaction Expected to Create Two Independent, Publicly Traded Companies with Distinct Strategic Priorities, Separate Capital Structures and Dedicated TeamsUp to $50 Million Committed to Adrenyx…
businesswire.com Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
benzinga.com Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target Citizens analyst Jonathan Wolleben reiterates Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and maintains $144 price target.- benzinga.com Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149 Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.
benzinga.com Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory StudyTA-ERT EAP and…- benzinga.com Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104 Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.
benzinga.com Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144 Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.- benzinga.com SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(6.68) per share which missed the analyst consensus estimate of $(5.80) by 15.17 percent. This is a 90.86…
- benzinga.com B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160 B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.
- benzinga.com Spruce Biosciences Joins Russell 3000 Index, Effective June 29 Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical…
benzinga.com Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.
benzinga.com Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135 Jones Trading analyst Catherine Novack initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $135.- benzinga.com Spruce Biosciences Presents Data Demonstrating Long-Term Benefit Of Tralesinidase Alfa Enzyme Replacement Therapy In Patients With Sanfilippo Syndrome Type B At 18th International MPS Symposium Data Highlight TA-ERT's Potential as the First Disease-Modifying Treatment Option for MPS IIIB, a Fatal Condition With No Approved TherapiesTreatment With Weekly TA-ERT Demonstrated Rapid and Durable…
- benzinga.com HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $200 to $150.
benzinga.com Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150 Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $170 to $150.- benzinga.com SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q1 EPS $(8.94) Misses $(8.78) Estimate SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(8.94) per share which missed the analyst consensus estimate of $(8.78) by 1.82 percent. This is a 62.75…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus (UPDATED) (Editor’s note: The futures and ETFs data were updated.) U.S. stock futures rose on Tuesday following Monday's decline. Futures of major benchmark indices edged up, with negotiating teams from the…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Amazon Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with Anthropic to spend $100B on AWS.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket 
benzinga.com Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com US Stocks Mixed; Dow Falls 100 Points - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Why Amplify Energy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Why Smith & Wesson Brands Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Gainers Impel Pharmaceuticals Inc. (NASDAQ: IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com $7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…
- benzinga.com Dow Jumps 700 Points; S&P 500 Rises Over 2% U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday.
- benzinga.com Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
- benzinga.com Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday.
- benzinga.com Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products…
- benzinga.com Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.